Renal cell carcinoma, VHL-associated

Section editor
	Ali Raza Khaki, MD Stanford University Palo Alto, CA arkhaki

Note: these are regimens tested in populations with a diagnosis of Von Hippel Lindau (VHL) Disease-associated renal cell carcinoma, please see the main RCC page for other regimens.

1 regimens on this page 1 variants on this page

All lines of therapy

Belzutifan monotherapy

back to top

Regimen

Study	Years of enrollment	Evidence
Awaiting publication (MK-6482-004)	2018-ongoing	Phase II (RT)

Note: dosing information is from the FDA labeling.

Targeted therapy

• Belzutifan (Welireg) 120 mg PO once per day

Continued indefinitely

References

1. MK-6482-004: NCT03401788